natgillin/translations-raw huggingface dataset:
Velmetia is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.
Zdravilo Velmetia je indicirano kot dodatek dieti in telesni vadbi za izboljšanje urejenosti glikemije pri bolnikih z neustrezno nadzorovano sladkorno boleznijo pri jemanju največjega odmerka samega metformina, ki ga prenašajo, ali pri bolnikih, ki že prejemajo kombinacijo sitagliptina in metformina.
Velmetia is also indicated in combination with a sulphonylurea (i. e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.
Zdravilo Velmetia je indicirano tudi v kombinaciji s sulfonilsečnino (tj. trojno kombinirano zdravljenje) kot dodatek dieti in telesni vadbi pri bolnikih z neustrezno nadzorovano sladkorno boleznijo pri jemanju največjega odmerka metformina, ki ga prenašajo, in sulfonilsečnine.
The dose of antihyperglycaemic therapy with Velmetia should be individualised on the basis of the patient ’ s current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100 mg sitagliptin.
Odmerek zdravila Velmetia pri antidiabetičnem zdravljenju je treba prilagoditi na podlagi bolnikovega trenutnega režima zdravljenja, učinkovitosti in tolerabilnosti, pri tem pa se ne sme preseči največjega dovoljenega odmerka 100 mg sitagliptina.
For patients inadequately controlled on maximal tolerated dose of metformin monotherapy For patients not adequately controlled on metformin alone, the usual starting dose of Velmetia should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) plus the dose of metformin already being taken.
Pri bolnikih z neustreznim nadzorom z največjim odmerkom metformina, ki ga prenašajo, pri samostojnem zdravljenju Pri bolnikih, pri katerih nadzor z metforminom samim ni ustrezen, mora dejanski začetni odmerek zdravila Velmetia zagotoviti odmerek 50 mg sitagliptina dvakrat na dan (skupni dnevni odmerek 100 mg) in odmerek metformina, ki ga že jemljejo.
For patients inadequately controlled on dual combination therapy with the maximal tolerated dose of metformin and a sulphonylurea The dose of Velmetia should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and a dose of metformin similar to the dose already being taken.
Pri bolnikih z neustreznim nadzorom pri dvojni kombinaciji z največjim odmerkom metformina, ki ga prenašajo, in sulfonilsečnino Odmerek zdravila Velmetia mora zagotoviti 50 mg sitagliptina dvakrat na dan (skupni dnevni odmerek 100 mg) in podoben odmerek metformina, kot ga že jemljejo.
When Velmetia is used in combination with a sulphonylurea, a lower dose of the sulphonylurea may be required to reduce the risk of hypoglycaemia (see section 4.4).
Kadar se zdravilo Velmetia uporablja v kombinaciji s sulfonilsečnino, bo morda potreben manjši odmerek sulfonilsečnine za zmanjševanje tveganja za hipoglikemijo (glejte poglavje 4. 4).
2 For the different doses on metformin, Velmetia is available in strengths of 50 mg sitagliptin and 850 mg metformin hydrochloride or 1000 mg metformin hydrochloride.
2 Za različne odmerke metformina je zdravilo Velmetia na voljo v jakostih po 50 mg sitagliptina in 850 mg metforminijevega klorida ali 1. 000 mg metforminijevega klorida.
Velmetia should be given twice daily with meals to reduce the gastrointestinal undesirable effects associated with metformin.
Zdravilo Velmetia je treba jemati dvakrat na dan ob obroku, da se zmanjšajo neželeni učinki metformina na prebavila.
Patients with renal insufficiency Velmetia should not be used in patients with moderate or severe renal impairment (creatinine clearance < 60 ml/ min) (see sections 4.3 and 4.4).
Bolniki z ledvično insuficienco Zdravila Velmetia se ne sme uporabljati pri bolnikih z zmerno ali hudo ledvično okvaro (kreatininski očistek < 60 ml/ min) (glejte poglavji 4. 3 in 4. 4).
Patients with hepatic insufficiency Velmetia should not be used in patients with hepatic impairment (see sections 4.3 and 5.2).
Bolniki z jetrno insuficienco Zdravila Velmetia se pri bolnikih z okvaro jeter ne sme uporabljati (glejte poglavji 4. 3 in 5. 2).
Elderly As metformin and sitagliptin are excreted by the kidney, Velmetia should be used with caution as age increases.
Starejši bolniki Metformin in sitagliptin se izločata skozi ledvice, zato je pri uporabi zdravila Velmetia pri starejših potrebna previdnost.
Paediatric population Velmetia is not recommended for use in children below 18 years of age due to a lack of data on its safety and efficacy in this population.
Pediatrična populacija Zaradi pomanjkanja podatkov o varnosti in učinkovitosti v tej populaciji uporabe zdravila Velmetia pri otrocih, mlajših od 18 let, ne priporočamo.
General Velmetia should not be used in patients with type 1 diabetes and must not be used for the treatment of diabetic ketoacidosis.
Splošno Zdravila Velmetia se ne sme uporabljati pri bolnikih s sladkorno boleznijo tipa 1 in za zdravljenje diabetične ketoacidoze.
Hypoglycaemia Patients receiving Velmetia in combination with a sulphonylurea may be at risk for hypoglycaemia.
Hipoglikemija Pri bolnikih, ki prejemajo zdravilo Velmetia v kombinaciji s sulfonilsečnino, se lahko pojavi tveganje za hipoglikemijo.
The use of Velmetia in combination with insulin has not been adequately studied.
Uporabe zdravila Velmetia v kombinaciji z insulinom niso dovolj raziskali.
If a hypersensitivity reaction is suspected, discontinue Velmetia, assess for other potential causes of the event, and institute alternative treatment for diabetes (see section 4.8).
Pri sumu na preobčutljivostne reakcije zdravljenje z zdravilom Velmetia prekinite, ocenite druge morebitne vzroke za ta neželeni učinek in začnite zdraviti sladkorno bolezen z drugimi zdravili (glejte poglavje 4. 8).
Surgery As Velmetia contains metformin hydrochloride, the treatment should be discontinued 48 hours before elective surgery with general, spinal or epidural anaesthesia.
Kirurški poseg Zdravilo Velmetia vsebuje metforminijev klorid, zato je treba zdravljenje prekiniti 48 ur pred elektivno operacijo pod splošno, spinalno ali epiduralno anestezijo.
Velmetia should not usually be resumed earlier than 48 hours afterwards and only after renal function has been re-evaluated and found to be normal.
Zdravljenje z zdravilom Velmetia se sme nadaljevati šele 48 ur po posegu in šele, ko se ugotovi normalno delovanje ledvic.
Therefore, Velmetia should be discontinued prior to, or at the time of the test and not reinstituted until 48 hours afterwards, and only after renal function has been re-evaluated and found to be normal (see section 4.5).
Zdravljenje se sme nadaljevati šele 48 ur po posegu in šele, ko se ugotovi normalno delovanje ledvic (glejte poglavje 4. 5).
4 Change in clinical status of patients with previously controlled type 2 diabetes A patient with type 2 diabetes previously well controlled on Velmetia who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis.
Spremembe kliničnega statusa pri bolnikih s predhodno nadzorovano sladkorno boleznijo tipa 2 Pri bolnikih s sladkorno boleznijo tipa 2, predhodno dobro nadzorovano z jemanjem zdravila Velmetia, pri katerih se pojavijo nenormalni izvidi laboratorijskih preiskav ali klinične bolezni (zlasti nejasne ali slabo opredeljene bolezni), je treba čim prej ugotoviti, če imajo ketoacidozo ali laktacidozo.
If acidosis of either form occurs, Velmetia must be stopped immediately and other appropriate corrective measures initiated.
Če se pojavi acidoza v katerikoli obliki, je treba zdravljenje z zdravilom Velmetia takoj prekiniti in primerno ukrepati.
Pharmacokinetic drug interaction studies with Velmetia have not been performed; however, such studies have been conducted with the individual active substances of Velmetia, sitagliptin and metformin.
Študije farmakokinetičnih interakcij zdravila Velmetia niso bile izvedene, vendar pa so take študije opravili s posameznima zdravilnima učinkovinama zdravila Velmetia, sitagliptinom in metforminom.
There is increased risk of lactic acidosis in acute alcohol intoxication (particularly in the case of fasting, malnutrition or hepatic insufficiency) due to the metformin active substance of Velmetia (see section 4.4).
Ker je v zdravilu Velmetia zdravilna učinkovina metformin, obstaja pri akutni zastrupitvi z alkoholom (še posebno v primerih stradanja, podhranjenosti ali jetrne insuficience) povečana nevarnost laktacidoze (glejte poglavje 4. 4).
Therefore, Velmetia should be discontinued prior to, or at the time of the test and not reinstituted until 48 hours afterwards, and only after renal function has been re-evaluated and found to be normal (see section 4.4).
Zdravljenje se sme nadaljevati šele 48 ur po posegu in šele, ko se ugotovi normalno delovanje ledvic (glejte poglavje 4. 4).
Velmetia should not be used during pregnancy.
Bolnice med nosečnostjo ne smejo uporabljati zdravila Velmetia.
If a patient wishes to become pregnant or if a pregnancy occurs, treatment with Velmetia should be discontinued and switched to insulin treatment as soon as possible.
Če želi bolnica zanositi ali če zanosi, je treba zdravljenje z zdravilom Velmetia prekiniti in čim prej preiti na zdravljenje z insulinom.
No studies in lactating animals have been conducted with the combined active substances of Velmetia.
Študij s kombinacijo zdravilnih učinkovin zdravila Velmetia na doječih živalih niso opravili.
Velmetia must therefore not be used in women who are breast-feeding (see section 4.3).
Zato ženske, ki dojijo, zdravila Velmetia ne smejo uporabljati (glejte poglavje 4. 3).
No studies on the effects on the ability to drive and use machines have been performed with Velmetia.
Študij o vplivu na sposobnost vožnje in upravljanja s stroji z zdravilom Velmetia niso izvedli.
In addition, patients should be alerted to the risk of hypoglycaemia when Velmetia is used in combination with other sulfonylurea agents.
Poleg tega je treba bolnike, ki jemljejo zdravilo Velmetia skupaj z drugimi zdravili, ki vsebujejo sulfonilsečnino, opozoriti na tveganje za pojav hipoglikemije.
There have been no therapeutic clinical trials conducted with Velmetia tablets however bioequivalence of Velmetia with co-administered sitagliptin and metformin has been demonstrated (see section 5.2).
Kliničnih terapevtskih preskušanj z zdravilom Velmetia niso izvedli, vendar pa so dokazali bioekvivalenco zdravila Velmetia in sočasne uporabe sitagliptina in metformina (glejte poglavje 5. 2).
During post-marketing experience of Velmetia or sitagliptin, one of the active substances of Velmetia, the following additional adverse reactions have been reported (frequency not known): hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria, and exfoliative skin conditions including Stevens-Johnson syndrome (see section 4.4).
V obdobju trženja zdravila Velmetia ali sitagliptina, eno od zdravilnih učinkovin zdravila Velmetia, so poročali o naslednjih neželenih učinkih (pogostnost ni znana): preobčutljivostne reakcije, vključno z anafilaktičnimi reakcijami, angioedemom, izpuščajem, urtikarijo in eksfoliativnimi stanji na koži, vključno s Stevens- Johnsonovim sindromom (glejte poglavje 4. 4).
No data are available with regard to overdose of Velmetia.
Podatki o prevelikem odmerjanju zdravila Velmetia niso na voljo.
Velmetia combines two antihyperglycaemic agents with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: sitagliptin phosphate, a dipeptidyl peptidase 4 (DPP-4) inhibitor, and metformin hydrochloride, a member of the biguanide class.
Zdravilo Velmetia je kombinacija dveh antidiabetičnih učinkovin s komplementarnim mehanizmom delovanja, namenjeno izboljšanju urejenosti glikemije pri bolnikih s sladkorno boleznijo tipa 2.
Sitagliptin differs in chemical structure and pharmacological action from GLP-1 analogues, insulin, sulphonylureas or meglitinides, biguanides, peroxisome proliferator-activated receptor gamma (PPAR γ) agonists, alpha- glucosidase inhibitors, and amylin analogues.
Sitagliptin se po kemijski strukturi in farmakološkem delovanju razlikuje od analogov GLP- 1, insulina, slulfonilsečnin ali meglitinidov, bigvanidov, agonistov receptorjev gama, aktiviranih s peroksisomskim proliferatorjem (PPARγ – peroxisome proliferator- activated receptor gamma), zaviralcev alfa- glukozidaze in analogov amilina.
in HbA1c (%) at Week 24 †
24.
at Week 24 †
tednu †
-0.7 ‡
– 0, 7
-0.9 ‡ (-1.1, -0.7)
(– 1, 1, – 0, 7) – 1, 6 ‡
-1.6 ‡ (-1.8, -1.3)
(– 1, 8, – 1, 3) – 2, 1 ‡
-2.1 ‡ (-2.3, -1.8)
(– 2, 3 – 1, 8)
Velmetia A bioequivalence study in healthy subjects demonstrated that the Velmetia (sitagliptin/ metformin hydrochloride) combination tablets are bioequivalent to co-administration of sitagliptin phosphate and metformin hydrochloride as individual tablets.
V bioekvivalenčni študiji pri zdravih osebah so pokazali, da so kombinirane tablete Velmetia (sitagliptin/ metforminijev klorid) bioekvivalentne sočasni uporabi sitagliptinijevega fosfata in metforminijevega klorida v obliki posameznih tablet.
EU/ 1/ 08/ 456/ 001 EU/ 1/ 08/ 456/ 002 EU/ 1/ 08/ 456/ 003 EU/ 1/ 08/ 456/ 004 EU/ 1/ 08/ 456/ 005 EU/ 1/ 08/ 456/ 006 EU/ 1/ 08/ 456/ 007 EU/ 1/ 08/ 456/ 015
EU/ 1/ 08/ 456/ 001 EU/ 1/ 08/ 456/ 002 EU/ 1/ 08/ 456/ 003 EU/ 1/ 08/ 456/ 004
Velmetia 50 mg/ 1000 mg film-coated tablets
Velmetia 50 mg/ 1. 000 mg filmsko obložene tablete
Capsule-shaped, red film-coated tablet with “ 577 ” debossed on one side.
Rdeče filmsko obložene tablete v obliki kapsule, z oznako "577" na eni strani.
17 For the different doses on metformin, Velmetia is available in strengths of 50 mg sitagliptin and 850 mg metformin hydrochloride or 1,000 mg metformin hydrochloride.
18 Za različne odmerke metformina je zdravilo Velmetia na voljo v jakostih po 50 mg sitagliptina in 850 mg metforminijevega klorida ali 1. 000 mg metforminijevega klorida.
19 Change in clinical status of patients with previously controlled type 2 diabetes A patient with type 2 diabetes previously well controlled on Velmetia who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis.
Spremembe kliničnega statusa pri bolnikih s predhodno nadzorovano sladkorno boleznijo tipa 2 Pri bolnikih s sladkorno boleznijo tipa 2, predhodno dobro nadzorovano z jemanjem zdravila Velmetia, pri katerih se pojavijo nenormalni izvidi laboratorijskih preiskav ali klinične bolezni (zlasti nejasne ali slabo opredeljene bolezni), je treba čim prej ugotoviti, če imajo ketoacidozo ali laktacidozo.
24 Velmetia combines two antihyperglycaemic agents with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: sitagliptin phosphate, a dipeptidyl peptidase 4 (DPP-4) inhibitor, and metformin hydrochloride, a member of the biguanide class.
Vsebuje sitagliptinijev fosfat, ki je zaviralec dipeptidil- peptidaze 4 (DPP- 4), in metforminijev klorid, ki spada med bigvanide.
-2.1 ‡ (-2.3, -1.8)
(– 2, 3, – 1, 8)
EU/ 1/ 08/ 456/ 008 EU/ 1/ 08/ 456/ 009 EU/ 1/ 08/ 456/ 010 EU/ 1/ 08/ 456/ 011 EU/ 1/ 08/ 456/ 012 EU/ 1/ 08/ 456/ 013 EU/ 1/ 08/ 456/ 014 EU/ 1/ 08/ 456/ 016
EU/ 1/ 08/ 456/ 008 EU/ 1/ 08/ 456/ 009 EU/ 1/ 08/ 456/ 010 EU/ 1/ 08/ 456/ 011
Outer carton for Velmetia 50 mg/ 850 mg film-coated tablets
Škatla zdravila Velmetia 50 mg/ 850 mg filmsko obložene tablete
Velmetia 50 mg/ 850 mg film-coated tablets sitagliptin/ metformin hydrochloride
Velmetia 50 mg/ 850 mg filmsko obložene tablete sitagliptin/ metforminijev klorid
EU/ 1/ 08/ 456/ 001 14 film-coated tablets EU/ 1/ 08/ 456/ 002 28 film-coated tablets EU/ 1/ 08/ 456/ 003 56 film-coated tablets EU/ 1/ 08/ 456/ 004 112 film-coated tablets EU/ 1/ 08/ 456/ 005 168 film-coated tablets EU/ 1/ 08/ 456/ 006 196 film-coated tablets EU/ 1/ 08/ 456/ 007 50 x 1 film-coated tablets EU/ 1/ 08/ 456/ 015 196 (2 x 98) film-coated tablets
EU/ 1/ 08/ 456/ 001 14 filmsko obloženih tablet EU/ 1/ 08/ 456/ 002 28 filmsko obloženih tablet EU/ 1/ 08/ 456/ 003 56 filmsko obloženih tablet EU/ 1/ 08/ 456/ 004 112 filmsko obloženih tablet EU/ 1/ 08/ 456/ 005 168 filmsko obloženih tablet EU/ 1/ 08/ 456/ 006 196 filmsko obloženih tablet EU/ 1/ 08/ 456/ 007 50 x 1 filmsko obloženih tablet EU/ 1/ 08/ 456/ 015 196 (2 x 98) filmsko obloženih tablet
Blister for Velmetia 50 mg/ 850 mg film-coated tablets
Pretisni omot zdravila Velmetia 50 mg/ 850 mg filmsko obložene tablete
Velmetia 50 mg/ 850 mg tablets sitagliptin/ metformin HCl
Velmetia 50 mg/ 850 mg tablete sitagliptin/ metformin HCl
Outer carton for Velmetia 50 mg/ 1,000 mg film-coated tablets
Škatla zdravila Velmetia 50 mg/ 1. 000 mg filmsko obložene tablete
Velmetia 50 mg/ 1,000 mg film-coated tablets sitagliptin/ metformin hydrochloride
Velmetia 50 mg/ 1. 000 mg filmsko obložene tablete sitagliptin/ metforminijev klorid
EU/ 1/ 08/ 456/ 008 14 film-coated tablets EU/ 1/ 08/ 456/ 009 28 film-coated tablets EU/ 1/ 08/ 456/ 010 56 film-coated tablets EU/ 1/ 08/ 456/ 011 112 film-coated tablets EU/ 1/ 08/ 456/ 012 168 film-coated tablets EU/ 1/ 08/ 456/ 013 196 film-coated tablets EU/ 1/ 08/ 456/ 014 50 x 1 film-coated tablets EU/ 1/ 08/ 456/ 016196 (2 x 98) film-coated tablets
EU/ 1/ 08/ 456/ 008 14 filmsko obloženih tablet EU/ 1/ 08/ 456/ 009 28 filmsko obloženih tablet EU/ 1/ 08/ 456/ 010 56 filmsko obloženih tablet EU/ 1/ 08/ 456/ 011 112 filmsko obloženih tablet EU/ 1/ 08/ 456/ 012 168 filmsko obloženih tablet EU/ 1/ 08/ 456/ 013 196 filmsko obloženih tablet EU/ 1/ 08/ 456/ 014 50 x 1 filmsko obloženih tablet EU/ 1/ 08/ 456/ 016 196 (2 x 98) filmsko obloženih tablet
Velmetia 50 mg 1,000 mg
Velmetia 50 mg 1. 000 mg
Blister for Velmetia 50 mg/ 1,000 mg film-coated tablets
Pretisni omot zdravila Velmetia 50 mg/ 1. 000 mg filmsko obložene tablete
Velmetia 50 mg/ 1,000 mg tablets sitagliptin/ metformin HCl
Velmetia 50 mg/ 1. 000 mg tablete sitagliptin/ metformin HCl
What Velmetia is and what it is used for 2.
Kaj je zdravilo Velmetia in za kaj ga uporabljamo 2.
Before you take Velmetia 3.
Kaj morate vedeti, preden boste vzeli zdravilo Velmetia 3.
How to take Velmetia 4.
Kako jemati zdravilo Velmetia 4.
How to store Velmetia 6.
Shranjevanje zdravila Velmetia 6.
WHAT VELMETIA IS AND WHAT IT IS USED FOR
KAJ JE ZDRAVILO VELMETIA IN ZA KAJ GA UPORABLJAMO
The name of your tablet is Velmetia.
Vaše zdravilo se imenuje Velmetia.
Velmetia helps to improve the levels of insulin after a meal and lowers the amount of sugar made by your body.
Zdravilo Velmetia pomaga povečati vrednosti insulina po obroku in zmanjšuje nastajanje sladkorja v telesu.
Velmetia can be used alone or with another medicine for diabetes called a sulphonylurea.
Zdravilo Velmetia se lahko uporablja samostojno ali skupaj z drugim zdravilom za sladkorno bolezen, imenovanim sulfonilsečnina.
BEFORE YOU TAKE VELMETIA
KAJ MORATE VEDETI, PREDEN BOSTE VZELI ZDRAVILO VELMETIA
Do not take Velmetia:
Ne jemljite zdravila Velmetia:
Velmetia (listed in section 6)
zdravila Velmetia (navedeno v poglavju 6). če imate diabetično ketoacidozo (zaplet sladkorne bolezni s hitrim hujšanjem, siljenjem na
taking Velmetia at the time of the X-ray and for a few days after
Zdravilo Velmetia morate prenehati jemati na dan rentgenskega pregleda in ga ne smete jemati še nekaj dni po njem.
Do not take Velmetia if any of the above apply to you.
Zdravila Velmetia ne jemljite, če karkoli od navedenega velja za vas.
If you are not sure, talk to your doctor or pharmacist before taking Velmetia.
Če niste prepričani, se, preden začnete jemati zdravilo Velmetia, posvetujte z zdravnikom ali s farmacevtom.
Take special care with Velmetia Check with your doctor or pharmacist before taking your medicine:
Bodite posebno pozorni pri uporabi zdravila Velmetia Pred začetkom jemanja zdravila se posvetujte z zdravnikom ali s farmacevtom:
Metformin hydrochloride, one of the ingredients in Velmetia, can cause a rare but serious side effect called lactic acidosis (a build-up of lactic acid in the blood) that can cause death.
Metforminijev klorid, ena izmed sestavin v zdravilu Velmetia, lahko povzroči redek, vendar resen neželeni učinek, imenovan laktacidoza (kopičenje mlečne kisline v krvi), ki je lahko smrtno nevaren.
If you experience some of the symptoms of lactic acidosis stop taking Velmetia and consult a doctor immediately
Če imate katerega izmed simptomov laktacidoze, prenehajte jemati zdravilo Velmetia in se takoj posvetujte z zdravnikom.
- During treatment with Velmetia, your doctor will check your kidney function at least once a
- med zdravljenjem z zdravilom Velmetia vam bo zdravnik preveril delovanje ledvic vsaj enkrat
year and more frequently if you are elderly or if your kidney function is borderline or at risk of worsening
na leto ali pogosteje, če ste starejši ali če je delovanje vaših ledvic na meji normalnega ali če obstaja tveganje za poslabšanje.
- if you have or have had an allergic reaction to sitagliptin, metformin, or Velmetia
- če imate ali ste imeli alergijsko reakcijo na sitagliptin, metformin ali zdravilo Velmetia.
- if you are taking a sulphonylurea, a diabetes medicine, together with Velmetia, as you may
- če jemljete sulfonilsečnino, zdravilo za sladkorno bolezen, skupaj z zdravilom Velmetia, saj
need to stop taking Velmetia for a couple of days before and after the procedure
boste smeli jemati zdravila Velmetia nekaj dni pred in po posegu.
If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before taking Velmetia.
Če niste prepričani, če karkoli od navedenega velja za vas, se, preden začnete jemati zdravilo Velmetia, posvetujte z zdravnikom ali s farmacevtom.
Taking Velmetia with food and drink Take Velmetia with meals to lower your chance of an upset stomach.
Jemanje zdravila Velmetia skupaj s hrano in pijačo Zdravilo Velmetia jemljite ob obrokih, da zmanjšate verjetnost želodčnih težav.
Pregnancy and breast-feeding Women who are pregnant or plan to become pregnant should talk to their doctor before taking Velmetia.
Nosečnost in dojenje Nosečnice in ženske, ki nameravajo zanositi, se morajo pred začetkom jemanja zdravila Velmetia posvetovati s svojim zdravnikom.
You should not use Velmetia during pregnancy.
Med nosečnostjo zdravila Velmetia ne smete uporabljati.
It is not known if Velmetia passes into human breast milk.
Ni znano, ali Velmetia prehaja v materino mleko.
You must not use Velmetia if you are breast-feeding or plan to breast-feed.
Če dojite ali nameravate dojiti, zdravila Velmetia ne smete jemati.
Driving and using machines No studies on the effects of Velmetia on the ability to drive or to use machines have been performed.
Vpliv na sposobnost upravljanja vozil in strojev Študije o vplivu zdravila Velmetia na sposobnost upravljanja vozil in strojev niso bile izvedene.
Taking Velmetia in combination with medicines called sulphonylureas can cause hypoglycaemia, which may affect your ability to drive and use machines or work without safe foothold.
Jemanje zdravila Velmetia v kombinaciji z zdravili, imenovanimi sulfonilsečnine, lahko povzroči hipoglikemijo, ki lahko vpliva na sposobnost vožnje in upravljanja strojev ali na delo v nevarnem okolju.
HOW TO TAKE VELMETIA
KAKO JEMATI ZDRAVILO VELMETIA
Always take Velmetia exactly as your doctor has told you.
Pri jemanju zdravila Velmetia natančno upoštevajte zdravnikova navodila.
• Velmetia should be taken:
• Zdravilo Velmetia vzemite:
• Continue to take Velmetia as long as your doctor prescribes it so you can continue to help control your blood sugar.
• Za nadzor sladkorja v krvi je pomembno, da zdravilo Velmetia jemljete tako dolgo, kot vam to predpiše zdravnik.
You should continue your diet during treatment with Velmetia and take care that your carbohydrate intake is equally distributed over the day.
Med zdravljenjem z zdravilom Velmetia nadaljujte z dieto in pazite, da ogljikove hidrate uživate enakomerno čez ves dan.